Health Canada has authorized Moderna to begin a Phase 1 clinical trial of an mRNA vaccine targeting the Bundibugyo strain of Ebola virus.
This trial represents a critical step in developing a medical countermeasure for a specific strain of the virus that has caused widespread fatalities. The effort comes as the international community seeks to curb a devastating surge of infections in Central Africa.
The trial began Aug. 4, 2026 [1], and will be conducted within Canada [2]. Researchers are recruiting 80 volunteers [3] for the first phase of the study. The primary goal of this initial stage is to evaluate the immune response triggered by the vaccine candidate [4].
The urgency of the research is driven by a crisis in the Democratic Republic of the Congo. That region is currently facing what has been described as the largest outbreak ever reported in the DRC [5]. Since May, health officials have recorded 3,800 infections [6].
The Bundibugyo strain has proven particularly lethal. Reports on the death toll vary slightly between sources, with figures ranging from more than 1,650 [7] to more than 1,700 deaths [8].
Moderna is utilizing the same mRNA technology that underpinned its COVID-19 vaccine to target the Ebola virus. By instructing cells to produce a protein that triggers an immune response, the company aims to create a rapid-response tool for future outbreaks. The trial in Canada will determine if the vaccine is safe and capable of inducing the necessary antibodies before moving to larger groups of participants [4].
“The trial represents a critical step in developing a medical countermeasure for a specific strain of the virus.”
The authorization of this trial highlights a shift toward using mRNA platforms for rapid-response vaccines against regional hemorrhagic fevers. Because the Bundibugyo strain is distinct from other Ebola variants, existing vaccines may not provide sufficient protection. Success in this Phase 1 trial would validate the speed of mRNA development for rare but high-fatality pathogens, potentially shortening the window between an outbreak's emergence and the deployment of a targeted vaccine.
